Genasense User Fee Date For CLL Extended Following New Data Submission
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has extended the action date for Genta's oblimersen 90 days.
You may also be interested in...
Genta Will Appeal FDA “Not Approvable” Action On Genasense
Company highlights supporting statements from medical experts in quest to overcome FDA’s position on valid CLL endpoints.
Genta Will Appeal FDA “Not Approvable” Action On Genasense
Company highlights supporting statements from medical experts in quest to overcome FDA’s position on valid CLL endpoints.
Genta Suffers Another Setback With Bcl-2 Inhibitor Genasense
Topline data from the firm’s Phase III study in treatment naive acute myelogenous leukemia patients fail to show survival benefit.